Cancer

With new Phase I/Ib results in kidney cancer, the HIF-2a inhibitor outshines Merck’s Welireg, but longtime Arcus partner Gilead decided not to exercise its option for casdatifan.

GSK’s depemokimab, if approved, could become the first ultra-long-acting drug for treating asthma and chronic rhinosinusitis with nasal polyps. Meanwhile, Sanofi’s teplizumab, which the US approved as the first disease-modifying therapy for type 1 diabetes in 2022, has now been filed for review by the European Medicines Agency.

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Just a few months after bagging US approval based on impressive progression-free survival data for its PI3K inhibitor, the Basel-headquartered giant is trumpeting a significant overall survival benefit for a drug that is expected to reinvigorate its breast cancer franchise.

Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions, as well as the potential of its Phase II asset bexmarilimab.

CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.

Acepodia’s dual-payload antibody-drug conjugates can link multiple tumor-killing agents without antibody modification. Apart from a GPC3-targeting candidate, the Taiwan-US biotech is also working on a bispecific antibody ADC with two different payloads, its CEO tells Scrip in an interview.

Scrip spoke with Lilly chief medical officer David Hyman at J.P. Morgan about the company’s oncology dealmaking strategy and plans for Scorpion’s selective PI3Kα-targeting asset.

The drug maker announced positive topline Phase III results for its subcutaneous PD-1 inhibitor sasanlimab in first-line, BCG-naïve non-muscle invasive bladder cancer combined with BCG.